Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Update

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the recipient of a large growth in short interest in June. As of June 30th, there was short interest totaling 1,511,367 shares, a growth of 336.3% from the June 15th total of 346,372 shares. Based on an average daily volume of 376,254 shares, the short-interest ratio is currently 4.0 days. Approximately 0.7% of the shares of the stock are sold short.

Hedge Funds Weigh In On Enlivex Therapeutics

Several hedge funds have recently bought and sold shares of ENLV. Jane Street Group LLC increased its position in Enlivex Therapeutics by 527.4% during the first quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock worth $78,000 after buying an additional 67,886 shares in the last quarter. Susquehanna International Group LLP purchased a new stake in shares of Enlivex Therapeutics in the third quarter valued at $57,000. Renaissance Technologies LLC boosted its stake in shares of Enlivex Therapeutics by 99.4% during the fourth quarter. Renaissance Technologies LLC now owns 313,628 shares of the company’s stock valued at $221,000 after acquiring an additional 156,336 shares during the last quarter. HRT Financial LP boosted its stake in shares of Enlivex Therapeutics by 719.4% during the fourth quarter. HRT Financial LP now owns 153,990 shares of the company’s stock valued at $108,000 after acquiring an additional 135,198 shares during the last quarter. Finally, XTX Topco Ltd increased its position in Enlivex Therapeutics by 44.8% during the 4th quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock worth $43,000 after purchasing an additional 19,132 shares in the last quarter. Hedge funds and other institutional investors own 1.02% of the company’s stock.

Trending Headlines about Enlivex Therapeutics

Here are the key news stories impacting Enlivex Therapeutics this week:

• Neutral Sentiment: HC Wainwright reiterated a Buy rating and a $300 price target on Enlivex Therapeutics, while making a series of small upward tweaks to its earnings estimates for FY2026, FY2027 and several quarterly periods. The revisions suggest the analyst remains constructive on the company’s longer-term outlook, but the adjustments were modest and do not appear to be enough on their own to offset recent selling pressure. Article Title
• Negative Sentiment: A separate market note framed ENLV as “Trading Down” and questioned whether it is a sell, which may have reinforced bearish sentiment among traders already focused on the stock’s weak recent trend and volatile volume. Article Title

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. HC Wainwright boosted their target price on Enlivex Therapeutics from $195.00 to $300.00 and gave the stock a “buy” rating in a research report on Tuesday, April 7th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Enlivex Therapeutics in a research note on Friday, June 26th. Finally, Wall Street Zen upgraded shares of Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, April 25th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $247.50.

Enlivex Therapeutics Stock Down 7.3%

Shares of ENLV traded down $0.54 during mid-day trading on Friday, reaching $6.86. 96,542 shares of the company’s stock were exchanged, compared to its average volume of 27,160. The company has a 50-day simple moving average of $10.15 and a two-hundred day simple moving average of $13.18. Enlivex Therapeutics has a 52-week low of $6.42 and a 52-week high of $31.50. The company has a market cap of $115.52 million, a price-to-earnings ratio of -0.83 and a beta of 1.52.

About Enlivex Therapeutics

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.